Literature DB >> 23704432

Neuroleptic malignant syndrome masked by cerebral malaria.

Kumar Muniandy Rajesh1, Vellan Sinnathamby, Arul N Sakthi.   

Abstract

A 38-year-old man with an underlying psychiatric illness presented with altered sensorium and abnormal behaviour. He was febrile at 38°C and weak looking; otherwise no other abnormalities were detected. A blood film conducted for malarial parasite (BFMP) revealed Plasmodium falciparum; hence a diagnosis of cerebral malaria was made. He was treated with antimalarial drugs for 2 days prior to being transferred out to the ward following clinical improvement. He subsequently developed episodes of stupor and refusal of feeding. Following an evaluation by the psychiatrist, a diagnosis of catatonic schizophrenia was made and he was started on oral sulpiride and benhexol. Unfortunately, he developed high-grade fever at 40°C with muscle rigidity and fasciculation. The diagnosis of neuroleptic malignant syndrome (NMS) was clinched and the antipsychotics were discontinued. However he succumbed to NMS several days later due to multiorgan failure.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23704432      PMCID: PMC3670014          DOI: 10.1136/bcr-2013-009061

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  8 in total

1.  Successful management of a patient with neuroleptic malignant syndrome associated with marked elevation of serum creatine kinase.

Authors:  Daisuke Takizawa; Koichi Nishikawa; Haruhiko Hiraoka; Hiroshi Hinohara; Shigeru Saito; Fumio Goto; Fumio Kunimoto
Journal:  J Anesth       Date:  2004       Impact factor: 2.078

Review 2.  Neuroleptic malignant syndrome.

Authors:  Jeffrey R Strawn; Paul E Keck; Stanley N Caroff
Journal:  Am J Psychiatry       Date:  2007-06       Impact factor: 18.112

Review 3.  Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology.

Authors:  G Northoff
Journal:  J Neural Transm (Vienna)       Date:  2002-12       Impact factor: 3.575

4.  Ziprasidone- and lithium-induced neuroleptic malignant syndrome.

Authors:  Mary C Borovicka; Linda C Bond; Kerri M Gaughan
Journal:  Ann Pharmacother       Date:  2005-12-13       Impact factor: 3.154

5.  Neuroleptic malignant syndrome. Diagnostic and therapeutic dilemmas in a general hospital setting.

Authors:  Naseem A Qureshi
Journal:  Neurosciences (Riyadh)       Date:  2008-10       Impact factor: 0.906

6.  Successful treatment of a complicated case of neuroleptic malignant syndrome.

Authors:  A Lappa; M Podestà; O Capelli; A Castagna; G Di Placido; D Alampi; F Semeraro
Journal:  Intensive Care Med       Date:  2002-06-07       Impact factor: 17.440

Review 7.  Neuroleptic malignant syndrome.

Authors:  S N Caroff; S C Mann
Journal:  Med Clin North Am       Date:  1993-01       Impact factor: 5.456

8.  Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations.

Authors:  Lara S Picard; Shane Lindsay; Jeffrey R Strawn; Rakesh M Kaneria; Nick C Patel; Paul E Keck
Journal:  Pharmacotherapy       Date:  2008-04       Impact factor: 4.705

  8 in total
  1 in total

1.  Trihexyphenidyl induced malignant hyperthermia in a patient with Parkinson's disease complicated with pneumonia: A case report.

Authors:  Jun Zhao; Gang Xu; Congrui Feng; Yuluo Chen; Yanhong Kang; Feng Liu; Wei Ma
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.